Cerebrolysin dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Injection / infusion | 5–30 mL/day | Once daily · 10–20 days |
| Oral | 30 mL | Single administration · Single visit |
Cerebrolysin dosage by administration route
Cerebrolysin injection / infusion (cerebrolysin) dosage
Cerebrolysin volumes are indication-specific, commonly 5–30 mL per day during a 10–20-day course. Intramuscular administration is limited to 5 mL; up to 10 mL can be given by direct IV injection, while 10–50 mL requires a slow IV infusion. An alternative schedule uses 5–30 mL daily by IV administration in 10–21-day courses and identifies the preparation as a supplied liquid. The upper IV volume must not be treated as an intramuscular volume; route-specific product limits still apply.[9][10]
Cerebrolysin is a mixture of porcine brain-derived peptides and amino acids. Treatment volumes and the administration method depend on the neurological indication and the specific product instructions.[1][2][3]
Cerebrolysin oral dosage
A documented historical oral exposure is a single 30 mL amount of a specific Cerebrolysin solution. This does not supply a current oral course or instructions to swallow injection ampoules.[5]
The historical oral solution contains a mixture of porcine brain-derived peptides and amino acids. It is a distinct administration context from the indication-specific injection and infusion products.[5][1][2][3]
Cerebrolysin dosage calculator
Convert your chosen Cerebrolysin amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.
Cerebrolysin safety and side effects
Side effects and long-term safety
Injection-related and neurologic symptoms are relevant tolerability concerns. Which neurologic populations benefit, how long benefits persist and how product variability affects safety remain uncertain.[1][2][3][4]
Route-specific dosing limits
Neurologic acuity, allergy risk and country-specific product oversight affect the safety of the particular injectable preparation. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[1][2][3][4][10]
